“Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early.”

Document Type

Presentation

Publication Date

5-1-2024

Keywords

washington; spokane

Clinical Institute

Kidney & Diabetes

Specialty

Endocrinology

Specialty

Nephrology

Comments

ADA

This document is currently not available here.


Share

COinS